Global sites currently include Australia, Belgium, Brazil, Canada, Czech Republic, Estonia, France, Germany, Hungary, Israel, Italy, Japan, Korea, Lithuania, Poland, Romania, Russian Federation, Spain, United Kingdom, and the United States.
Napabucasin is an orally administered investigational agent designed to inhibit cancer stem cell pathways by targeting STAT3.
Preliminary results of napabucasin plus paclitaxel as second-line therapy in patents with advanced gastric and GEJ adenocarcinoma were published as a poster at the ASCO Annual Meeting 2015. Click here to download the poster. Napabucasin is an investigational agent and not approved by the US FDA.
Boston Biomedical is a biopharmaceutical company focused on the research and development of novel cancer therapeutics targeting cancer stem cell pathways.
‡Study locations noted above are as of May 2016